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AbstrAct
Objective Perfusion-metabolism mismatch pattern on 
positron emission tomography (PET) predicts hibernating 
myocardium. We assess the ECG-gated metabolic PET as a 
surrogate for the perfusion-metabolism mismatch pattern 
on PET imaging.
Methods 13N-Ammonia (NH3) and 
18F-fluorodeoxyglucose 
(FDG) are respectively perfusion and metabolism PET 
tracers. We used ECG gating to acquire FDG-PET to collect 
wall thickening (mechanical) data. These allow detection 
of metabolic activity in regions with reduced contraction 
(metabolism-mechanical mismatch pattern). We had 
two data sets on each patient: perfusion-metabolism 
and metabolism-mechanical data sets. We tested the 
hypothesis that metabolism-mechanical pattern on PET 
could predict perfusion-metabolism mismatch pattern.
Results We studied 55 patients (48 males), mean age 
62 years. All were in sinus rhythm, and had impaired left 
ventricular contraction. Perfusion-metabolism mismatch 
pattern was found in 26 patients. Metabolism-mechanical 
mismatch pattern was found in 25 patients. The results 
were concordant in 52 patients (95%). As a surrogate for 
perfusion-metabolism mismatch pattern, demonstration 
of metabolism-mechanical mismatch pattern is highly 
sensitive (92%) and specific (97%). In this cohort, the 
positive and negative predictive accuracy of the new 
method are 96% and 93%, respectively.
Conclusion Metabolism-mechanical mismatch pattern 
could predict perfusion-metabolism mismatch pattern 
in patients with myocardial viability criteria on PET. 
Prospective validation against the gold standard of 
improved myocardial contraction after revascularisation is 
needed.
IntroductIon
It is important to predict the presence of 
viable and potentially hibernating myocar-
dium preoperatively. This stems from 
increased mortality rates of the patients with 
heart failure,1 the relatively high prevalence 
of viability in those with severe left ventricular 
impairment2 and their improved prognosis 
following revascularisation.3
The classic positron emission tomography 
(PET) methods of preoperative prediction 
of viable and hibernating myocardium is the 
presence of perfusion-metabolism mismatch 
pattern.4 This uses dual radioisotope imaging 
Key MessAges
What is already known about this subject?
Perfusion-metabolism mismatch pattern on positron 
emission tomography (PET) is one of the gold 
standards for predicting and detecting hibernating 
myocardium. However, this requires both a perfusion 
marker and a metabolism marker. The perfusion 
marker is a short-acting agent necessitating the 
presence of a cyclotron on site. In addition, there are 
occasional difficulties in ensuring the superimposition 
of the perfusion and the metabolism scans. We have 
already demonstrated the reliability of the ECG-gated 
metabolic scans in assessing myocardial contraction 
and thickening in comparison to the cine cardiac MRI 
scans. Finally, several investigators have confirmed 
that the presence of metabolic activity in a myocardial 
segment beyond a threshold of usually 50% is 
associated with viability.
What does this study add?
 ► The possibility of producing two sets of data from 
using a single marker to define both metabolic and 
mechanical activity of the myocardium.
 ► The predictability of the PET gold standard 
marker of hibernating myocardium using ECG-
gated 18F-fluorodeoxyglucose-PET.
How might this impact on clinical practice?
 ► The possibility of performing tests of myocardial 
hibernation using a long-acting metabolic markers 
in centres where a cyclotron is not available on 
site, if the hypothesis is proven prospectively.
 ► New definition of hibernating myocardium 
using the mismatch between metabolism and 
mechanical defects when proven could be more 
representative of the pathophysiology particularly 
given the continuing dilemma of whether 
hibernating myocardium suffers from chronic 
hypoperfusion or repetitive stunning.
 ► However, these benefits could not be realised until 
the hypothesis is proven prospectively.
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technique. We are reporting the retrospective testing of 
the predictability of the perfusion–metabolism mismatch 
pattern, through the use of ECG-gated metabolic myocar-
dial images, thus using a single radio-isotope.5 6 The new 
method relies on combining information on myocardial 
metabolism and thickening. We propose that impaired 
but viable myocardium could be probably predicted by 
demonstrating continuing metabolic activity in a region 
with reduced myocardial thickening (metabolic-mechan-
ical mismatch pattern).
Methods
subjects
The patients were consecutive patients attending the 
John Mallard Scottish PET Centre for the detection of 
myocardial viability. The patients underwent the PET 
studies investigating the presence of hibernating myocar-
dium in more than one study approved by the ethical 
committee. All the patients contributing to this investiga-
tion were in sinus rhythm (for feasibility of ECG gating), 
and had severe left ventricular systolic impairment, with 
left ventricular ejection fraction <35% as measured by 
modified Simpson method. All the patients had ischaemic 
heart disease causing their left ventricular impairment.
ethical committee approval
The patients gave informed written consent before 
undergoing PET. The imaging protocol was approved by 
the local research ethics committee.
Positron emission tomography
All the patients had perfusion and metabolic imaging 
using PET. The perfusion assessment used 13N-ammonia 
(13N-NH3).
7 The metabolism assessment used 18F-2 fluo-
ro-2-deoxyglucose (18F-FDG),8 which was acquired using 
an ECG-gated mode. The data were then re-visited and 
divided into two sets of data for each patient: the first set 
was combined perfusion-metabolism data and the second 
set was the combined data of metabolism and wall thick-
ening. The latter was gained by acquiring the 18F-FDG 
images in an ECG-gated mode.
Tomographic imaging was performed using a Siemens 
ECAT EXACT 31 PET scanner, which produces 31 slices, 
the slice separation is 3 mm and the reconstructed image 
resolution is 10 mm. Attenuation correction is achieved 
by a transmission scan using three revolving rod sources 
prior to the emission scan.
13N-NH3 was given intravenously at a dose of 370 MBq 
(1.5 mSv). Volume images of myocardial uptake were 
then gathered up to 20 min after injection.
18F-FDG was injected intravenously at a dose of 185 
MBq (0.5 mSv), 1 hour following an oral glucose load 
of 50 g of glucose.9 Patients with diabetes received 4–10 
units of intravenous soluble insulin to keep their serum 
glucose level between 4 and 11 mmol/L. The patient was 
positioned with careful attention to alignment based 
on markers put on the chest wall and using laser beams 
created by the scanner at the time of positioning; we were 
able to ensure that the patient’s position was the same 
during both scans.10 The 18F-FDG uptake images were 
acquired 60 min postinjection.
the ecg-gated acquisition of data
The 18F-FDG uptake images were acquired in an 
ECG-gated mode, with imaging data gathered at the R 
wave.5 6 Wall thickening assessment to produce regional 
wall motion analysis by ECG-gated 18F-FDG was done in 
the following fashion: myocardial uptake was measured 
by reforming the ventricle into four short-axis sections 
covering the base to mid-ventricle. The apex to mid-ven-
tricle was reformed as eight long-axis sections at 22.5° 
intervals round the ventricle's long axis. Radial profiles 
were formed at 22.5° intervals round each short-axis 
section producing 16 profiles for each short-axis section. 
Five radial profiles were formed at 30° intervals from 
each of the long-axis sections. This three-dimensional 
sampling profile set more closely reflects the most likely 
wall thickening direction than simple short-axis sampling. 
A complete set of wall profiles was obtained at each of 
eight phases using a fixed laboratory frame of reference. 
Each profile was analysed to obtain a hybrid wall thick-
ness parameter given by the product of maximum wall 
uptake in the profile and the ‘thickness’ of the wall as 
given by the second moment of the radial profile. Use 
of the second moment of radial profile allows for partial 
volume effect.11 The product of uptake and apparent 
thickness has been shown to be more linearly related to 
actual wall thickness than the individual parameters.12 
The time variation in hybrid wall thickness for each 
profile direction was Fourier analysed to obtain an ampli-
tude and phase value. The amplitude was subsequently 
converted into a percentage wall thickening value. The 
variation in wall thickening was converted into a polar 
map representation.
Production of polar maps
The reconstructed images were rotated and re-sliced 
to generate short-axis sections of the myocardium, 
which were subsequently analysed using circumference 
profile analysis to produce polar maps diagrammati-
cally showing the myocardial distribution of the tracers 
(figure 1).11 The left ventricle as represented by the 
polar map was divided into two regions: anterior and 
inferior.
determination of the perfusion-metabolism mismatch 
pattern
The myocardial region with the highest uptake of 13N-
NH3 was taken as the reference 
13N-NH3 level for that 
patient. The abnormally perfused areas were semiquan-
titatively compared with the reference area. The glucose 
uptake in that reference area was regarded as the refer-
ence 18F-FDG level of uptake for that particular patient. 
The rest of the myocardium was then compared with 
this reference level.
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Figure 1 The figure shows three polar maps. (1) Perfusion 
polar map using 13N-ammonia showing severe reduction of 
perfusion in the septum and the apex. There is a relatively 
mildly reduced perfusion in the lateral wall. (2) Metabolism 
polar map using 18F-fluorodeoxyglucose (FDG) showing the 
glucose uptake is particularly raised in the base of the infero-
lateral wall, resulting in (3) the difference map showing the 
perfusion-metabolism mismatch in the base of the infero-
lateral wall. 
Figure 2 The motion map (1) shows that there is profound 
reduction of motion in most of the left ventricle, in keeping 
with severe left ventricular impairment particularly in the 
base of the infero-lateral wall. The metabolic map (2) shows 
that glucose uptake is particularly raised in the base of 
the infero-lateral wall. The difference map (3) shows the 
mechanical metabolic mismatch pattern very similar to that 
of the perfusion-metabolism mismatch in the base of the 
infero-lateral wall.
Heart failure and cardiomyopathies
Areas of the myocardium with perfusion-metabolism 
mismatch pattern were thus identified.2 The assessment 
of mismatch pattern was carried out qualitatively by simul-
taneous inspection of perfusion and metabolism images.
determination of metabolism-mechanical mismatch pattern
The region with the best degree of wall thickening is 
considered as the reference region for wall thickening, 
and its 18F-FDG uptake was considered as the reference 
level of 18F-FDG uptake. It is known that areas with 18F-
FDG uptake higher than 50% of the reference area 
are viable.13 Subsequently, the wall thickening of these 
regions was then determined. Metabolic-mechanical 
mismatch pattern was considered to be present if the 
18F-FDG uptake was higher than 50% of the reference 
area with severely reduced (<50% of the normal wall 
thickening) or absent wall thickening. The latter could 
be semiquantitatively assessed by taking a wall thickening 
threshold of 50% of the thickening in the reference 
area, as the level below which the contraction is taken 
to be significantly impaired (figure 2). The reliability of 
gated 18F-FDG imaging as a method of assessing myocar-
dial thickening and therefore reflecting the mechanical 
aspect of myocardial function has been confirmed by our 
group.6
comparison between the two data sets
The two data sets were then compared with look at the 
concordance of the results, and the predictability of the 
perfusion-metabolism mismatch pattern, by using the 
metabolism-mechanical mismatch pattern as surrogates.
statistics
Continuous variables are presented as mean ± SD. Cate-
gorical data are presented as frequencies. Data were 
analysed using SPSS for Microsoft Windows Release V. 6.1 
software package.
results
There were 55 patients (48 males) in sinus rhythm, 
with a mean±SD age of 62.4±8.6 years, with confirmed 
ischaemic heart disease as the aetiology for the left 
ventricular systolic impairment. The latter was based on 
the measurement of left ventricular ejection fraction 
using the modified Simpson’s method at <35%. The risk 
factors’ profile of the patients is shown in table 1. Of the 
55 patients included in the study, data on their coronary 
angiograms revealed occlusion of one or more coronary 
artery in 40 patients. Not all of these occlusions were asso-
ciated with a clear history of acute coronary syndrome 
that the patient had recalled. Of the remaining patients, 
four patients had a definite ST elevation myocardial 
infarction (STEMI) in the past treated at the time with 
thrombolysis. There was no definite history of STEMI in 
the remaining 11 patients.
The intra-observer variability was 94%. The two 
observers who determined the defects, resolved their 
differences by consensus.
Perfusion-metabolism mismatch pattern was present 
in 26 patients. The ECG-gated 18F-FDG images revealed 
that 25 patients had metabolism-mechanical mismatch 
pattern. Two of the patients with perfusion-metabolism 
mismatch pattern did not have concordant metabo-
lism-mechanical mismatch pattern. On the other hand, 
one patient with metabolism-mechanical mismatch 
pattern did not have a concordant perfusion–metabolism 
mismatch pattern.
At regional level, there were 26 patients with perfu-
sion-metabolism mismatch pattern. Of those, two 
patients did not have concordant metabolism-mechanical 
mismatch pattern. A 27th patient had metabolism-me-
chanical mismatch pattern with no perfusion-metabolism 
mismatch pattern. Of the 24 remaining patients with 
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Table 1 Patients’ characteristics and risk factors
Characteristic Incidence
Age (mean ± SD) 62.4±8.6 years
Male gender 87%
Diabetes mellitus 16%
Hypertension 27%
Hypercholesterolaemia 89%
Positive family history 55%
Positive smoking history 76%
Figure 3 Comparison between the metabolic mechanical 
imaging and perfusion metabolic imaging in the same 
patients. The figure demonstrates the high positive and 
negative predictive values of gated metabolic imaging, 
in relation to the dual perfusion and metabolic imaging 
by positron emission tomography. MM, metabolic-
mechanical mismatch PM, perfusion-metabolic mismatch.
concordant perfusion-metabolism mismatch pattern and 
metabolic-mechanical mismatch pattern scoring, the 
mismatch area was identical in size in 18 patients. The 
estimate of the size of the mismatch region was different 
in six patients. The accuracy of the size of the mismatch 
pattern may vary between the two methods in up to 6 of 
the 24 patients with concordant perfusion-metabolism 
and metabolism-mechanical mismatch patterns (25%). 
The results taking into consideration the total cohort 
(those with and without mismatch pattern on perfu-
sion-metabolism assessment by PET) were concordant in 
52 of the 55 patients (95%).
The metabolism-mechanical mismatch pattern as a 
surrogate marker for the classical perfusion–metabo-
lism mismatch pattern is sensitive (92%) and specific 
(97%). In this cohort, it has excellent positive and nega-
tive predictive accuracies: 96% and 93%, respectively. 
(figure 3).
dIscussIon
Hibernating myocardium is defined by its recovery 
following revascularisation.14 It is advisable to preoper-
atively detect the presence of hibernating myocardium 
by an imaging technique in the patients with severe 
left ventricular impairment, using one of the imaging 
techniques.15 The PET preoperative detection of hiber-
nating myocardium is one of these techniques. It relies 
on demonstrating continuing metabolism of glucose 
in areas of underperfusion, the perfusion-metabo-
lism mismatch pattern.8 16 17 Pathophysiologically, this is 
based on the fact the ischaemic myocardium switches to 
mainly anaerobic metabolism of glucose in lieu of free 
fatty acids.18
The metabolic PET marker of glucose metabolism is 
the extrinsic glucose analogue 18F-FDG. The use of the 
combination of perfusion and metabolic imaging, with 
13N-NH3 and 
18F-FDG, respectively, is the most commonly 
used PET combination to detect hibernating myocar-
dium,19 and has high positive and negative predictive 
accuracies of functional improvement with myocardial 
revascularisation.8 16 20
Allman et al. carried out a meta-analysis of 24 obser-
vational studies of 3088 patients and concluded that 
single-photon emission computed tomography (SPECT) 
and PET-based imaging have similar abilities in the 
prediction of survival benefit after revascularisation.21 In 
contrast, Rohatgi et al. showed that myocardial viability 
was present by PET in 60% of the myocardial regions 
classified as scarred by thallium SPECT in patients with 
ischaemic left ventricular systolic impairment,22 and 
detected a significant improvement in survival after revas-
cularisation in these patients compared with medical 
treatment alone.22
Gated 18F-FDG PET is known to be useful in assessing 
myocardial contraction and left ventricular ejection frac-
tion.23 We have previously confirmed its usefulness in this 
regard when compared with cardiac MRI.6
In this study, we propose a new PET-based method 
for the prediction of hibernating myocardium, which 
may provide a new definition of the phenomenon. We 
found that metabolism-mechanical mismatch pattern by 
gated 18F-FDG PET could predict the presence of perfu-
sion-metabolism mismatch pattern with high sensitivity, 
specificity, positive and negative predictive accuracy. 
Our study lacked the confirmation of the predictability 
of hibernation through the demonstration of improved 
contraction after revascularisation. This study is a retro-
spective examination of already acquired two sets of data. 
The latter two are limitations to our study.
The new aspect of our study is the combination of 
metabolism and mechanical (wall motion and thick-
ness) assessments using a single radiopharmaceutical 
agent. The proposition is that the metabolism-mechan-
ical mismatch pattern will detect and potentially offer a 
new definition of hibernating myocardium. The latter 
would, we recognise, require prospective assessment 
of the proposed definition using the gold standard for 
identifying hibernating myocardium which is improved 
myocardial contraction following revascularisation. If 
proven, the new definition would also allow the use of 18F-
FDG PET in centres where there is no on-site cyclotron, 
and thus there is no access to the perfusion short-acting 
PET markers.
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We do recognise, however, that reliance on metabolic 
imaging by 18F-FDG PET is not free from problems 
related to the difficulties in achieving optimal uptake 
of the tracer in patients with diabetes. Some argue that 
in the absence of perfusion data one may have difficulty 
ascertaining and interpreting the metabolism data. One, 
however, could argue that this may be related to our 
collective habit of assessing metabolism in combination 
with perfusion and it may be that once the new concept 
had been verified prospectively using the gold standard 
for the definition of hibernating myocardium, the cohort 
of those performing this type of cardiac imaging may 
begin to use the metabolism and the mechanical data in 
combination in a way similar to our current reliance on 
perfusion when we assess metabolism data.
In the past, Gerber et al., from the European Commu-
nity Concerted Action Multicenter study on use of 18F-FDG 
PET for the Detection of Myocardial Viability, confirmed 
that it is possible to predict myocardial viability by using 
18F-FDG PET. They used hyperinsulinemic euglycemic 
clamp and 18F-FDG PET prerevascularisation and postrev-
ascularisation (coronary artery bypass grafting (CABG) 
or angioplasty). The accuracy was 67%, their technique 
had a high sensitivity of 79% and a specificity of 55% 
when there were at least three dysfunctional myocardial 
segments with FDG uptake >45% of that in the remote 
normal segments.24
Fath-Ordoubadi et al. proposed as a result of their study 
of hibernating myocardium using quantitative technique 
of perfusion reserve and metabolic rate of glucose after 
using the glucose clamp a threshold value for the meta-
bolic rate of glucose of ≥0.25 μmol/g/min that would 
allow the best prediction of improvement in functional 
class of at least one grade after revascularisation.25
The findings of both Gerber et al. and Fath-Ordoubadi 
et al. are superior to ours on the basis that they included 
the ultimate confirmation of the presence of hibernating 
myocardium by assessing the outcome following revascu-
larisation. Both studies used euglycaemic glucose clamp 
which improves the quality of images in patients with 
diabetes.19
We do recognise that the interpretation of the meta-
bolic images may be problematic if taken alone with no 
perfusion imaging, as the behaviour of the myocardial 
metabolism varies between those with normal myocardial 
flow and those with ischaemia. When we analysed the 
metabolism-mechanical data, the analysing investigator 
was blinded to the perfusion data already collected on 
the patients.
We also note the entity of reverse perfusion-metabolism 
mismatch that is rarely seen where the perfusion is not 
decreased but the metabolism is decreased. The interpre-
tation of the latter is difficult in any case. Such rare cases 
could be missed if one was using a single metabolic agent 
(as we proposed), with no perfusion data. This is a poten-
tial pitfall.
It is important if this new concept of metabolism-me-
chanical mismatch pattern was tested prospectively, that 
an assessment is made of the critical mass of myocardium 
thus predicted as potentially hibernating necessary to 
make a clinical difference if the patient was to be revas-
cularised. We do know from other techniques that 5 
segments of the 17-segment model of the left ventricular 
myocardium is regarded as the threshold for revascular-
isation in these patients to result in an improved clinical 
outcome. Similar tests need to be carried out if we were 
testing this new concept.
Our study is simply a pilot study that showed the poten-
tial feasibility of an alternative method for the prediction 
of hibernating myocardium using a single radiopharma-
ceutical, and an alternative PET definition of hibernating 
myocardium. If prospectively confirmed by improved 
contraction after revascularisation, metabolism-mechan-
ical mismatch pattern by ECG-gated 18F-FDG PET could 
provide an easier way to perform PET detection of hiber-
nating myocardium (through access to the technique 
to centres that do not have a cyclotron on site), and a 
new PET definition of hibernation linking the absence 
or significant reduction of mechanical activity to the 
continuing metabolic activity.
other potential limitations to the proposed concept
First, its utility is limited to the patients who are in normal 
sinus rhythm. Second, the poor myocardial uptake of 
glucose in patients with diabetes results in much reduced 
counts when the glucose uptake data are acquired in an 
ECG-gated mode. This could limit the use of this new 
diagnostic method in patients with diabetes who consti-
tute around 24% of the patients with ischaemic heart 
disease and significant left ventricular systolic impair-
ment, although in this study cohort diabetes mellitus 
affected only 16% of the patients.
conclusIon
Metabolism-mechanical mismatch pattern could predict 
perfusion-metabolism mismatch pattern on PET in 
patients with myocardial viability. Prospective valida-
tion against the gold standard of improved myocardial 
contraction after revascularisation is needed.
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